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Angiogenesis has developed into a major area of cancer research. Recently, several newly identified signalling pathways have been
shown to play a role in both normal and pathological (including tumour) angiogenesis. Several of the molecules involved in these
pathways have potential as novel anti-cancer therapeutic targets including members of the ephrin/Eph receptor, Notch/delta, sprouty,
hedgehog and roundabout/slit families. These developments are reviewed.
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Angiogenesis describes the formation of new blood vessels from
the existing vasculature, a process that is relatively rare in the
healthy human adult, occurring only during the female menstrual
cycle and in wound healing. In contrast, angiogenesis occurs in
many pathologies including diabetic retinopathy, arthritis, athero-
sclerosis, psoriasis and tumour growth. It has long been postulated
that abrogation of angiogenesis could be an effective anticancer
strategy; however, in order to be able to design effective
antiangiogenic treatments, we must first understand how new
blood vessels form. The inception of the vascular system occurs
early in mammalian development with the differentiation and
aggregation of angiogenic precursors in the embryo culminating in
the blood islands of the visceral yolk sac. The early blood vessels of
the embryo and yolk sac develop by aggregation of angioblasts that
de novo create a primitive network of simple endothelial tubes –
the process of vasculogenesis. Extensive research into the
molecular mechanisms involved in vessel formation has identified
proangiogenic factors such as vascular endothelial growth factor
(VEGF) and the angiopoietins, together with antiangiogenic factors
such as the thrombospondins and transcription factors leading to
their expression like Id1 (reviewed in Bikfalvi and Bicknell, 2002).
Two recent developments in the field have been the delineation of
the mechanism by which hypoxia acts as a proangiogenic stimulus
via the oxygen-sensing prolyl hydroxylase and hypoxia-inducible
factor-a and the identification of several novel extracellular
angiogenic signalling pathways. The latter include the ephrin/
Eph receptor, notch/delta, hedgehog, sprouty and slit/roundabout
families (Figure 1). Here, we review the role of these signalling
pathways in angiogenesis and point out where appropriate as to
how they could be utilised to develop new anticancer strategies.
EPHRINS, THE EPH TYROSINE KINASE RECEPTORS
AND ANGIOGENESIS: VALIDATED ANTITUMOUR
TARGETS
The ephrin ligands and Eph receptors comprise an increasingly
studied family of signalling molecules originally identified some 13
years ago. Like other families of signalling molecules, they are not
restricted to the endothelium, but are found in numerous cell
types. Also, like the notch/delta family described later, the ephrin
ligands and their Eph receptors are both membrane-bound
molecules. The ephrin ligands are divided into A and B type
molecules that are distinguished by the way in which they are
anchored in the plasma membrane. Thus, the ephrin A ligands are
tethered to the outer plasma membrane via a glycosylpho-
sphatidylinositol (GPI) anchor, whereas the ephrin B ligands are
inserted into the plasma membrane via a transmembrane region
followed by a conserved cytoplasmic domain. The ephrins bind to
two families of transmembrane EphA and EphB tyrosine kinase
receptors. While the A-type ephrins preferentially bind to the
EphA receptors and the B-type ephrins to the EphB receptors,
within each subclass, considerable promiscuity of receptor binding
has been demonstrated.
Several ephrins and Eph receptors have been found in the
vascular endothelium. These include ephrin A1 that plays a role in
the inflammatory angiogenesis induced by tumour necrosis factor-
a (Pandey et al, 1995) and ephrin B1 that promotes endothelial
capillary-like assembly and attachment in vivo (Stein et al, 1998).
Ephrin B2 and the eph receptors EphB3 and EphB4 are also present
in vascular endothelium. The involvement of ephrin ligands and
ephrin receptors in vascular development is already so extensive
that it is not feasible to review all the studies here. Interested
readers are referred to recent reviews (Adams, 2002; Cheng et al,
2002a). A clear role for ephrins in normal vascular development
presaged a role in pathological tumour angiogenesis.
EPHRIN LIGANDS AND EPH RECEPTORS IN TUMOUR
ANGIOGENESIS
A detailed study by Ogawa et al (2000) showed that the ephrin A1
ligand and its EphA2 receptor are expressed in tumour angiogen-
esis. Thus, double immunostaining of endothelial cells for CD34
showed ephrin A1 and its EphA2 receptor to be expressed
throughout the endothelium in mouse xenografts of human
MDA435 and K1767 Kaposi sarcoma cells and in the vasculature
of human cancers. A dominant-negative EphA2 receptor blocked
the formation of capillary endothelial tubes in vitro. Further
studies have shown that soluble EphA2-Fc and EphA3-Fc receptor
constructs inhibit tumour angiogenesis and growth in vivo
(Brantley et al, 2002), providing the first functional evidence for
EphA receptor regulation of tumour angiogenesis. Recent mechan-
istic studies have shown that blockade of the EphA receptor
specifically inhibits VEGF-induced angiogenesis (Cheng et al, Received 28 March 2003; accepted 9 May 2003
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as Martiny-Baron et al (2001) have reported similar effects with the
soluble extracellular domains of the ephrinB2 and EphB4
receptors. There is clearly much work to do, but it appears that
abrogation of the function of both the A and B class ephrins may
provide novel antiangiogenic and antitumour activites.
NOTCH SIGNALLING IN ANGIOGENESIS
The construction of a multicellular organism with characteristic
size and shape from a single cell requires complex coordinated
gene action to direct the fate of each cell. An organism will often
use the same signalling pathway within different cellular contexts
to achieve unique developmental objectives. Originally charac-
terised in Drosophila (Artavanis-Tsakonas et al, 1999), the Notch
receptor and its ligands Delta/Serrate are one example of such a
signalling system that plays many roles throughout development,
as well as affecting cell cycle progression and apoptosis.
The complexity of the Notch system in vertebrates is illustrated
by the existence of multiple Notch receptors and ligands, each
having a distinct expression profile. Thus, there are four Notch
receptors in man, Notch 1–4 and five ligands, Jagged1 and 2 and
Delta (Dll)1, -3 and -4. The activation of Notch upon ligand
binding is accompanied by proteolytic processing that releases an
intracellular domain of Notch (NICD) from the membrane. The
intracellular domain then translocates to the nucleus where it
associates with the CSL family of DNA-binding proteins to form a
transcription factor. This complex initiates the transcription of a
set of target genes, including the Enhancer of Split group E(spl)
and others; in this way Notch functions as a membrane-bound
transcription factor. That Notch is active during human vascular
development is illustrated by the cerebral disorder, cerebral
autosomal-dominant arteriopathy with subcortical infarcts and
leucoencephalopathy (CADASIL), which arises from a mutation in
Notch3. CADASIL is characterised by stroke, vascular dementia
and arteriopathy of cerebral arterioles.
Direct evidence from several other studies has indicated a role
for Notch signalling during vascular development as well as during
maintenance of vessel homeostasis in the adult. When an activated
form of the Notch4 protein is under the regulation of the Flk1
(VEGFR) promoter in mice during embryonic development, the
expression of this activated Notch results in growth and
developmental delay and embryonic lethality at embryonic day
10 (Uyttendaele et al, 2001). These mice had fewer vascular
networks and those that did form were disorganised with less small
vessels present. A similar phenotype was observed when Jagged1
was inactivated in the mouse embryo (Xue et al, 1999). Finally,
haemorrhage was observed in delta1 mutants (Hrabe de Angelis
et al, 1997). In fact, both increases and decreases in Notch
signalling in mice produce similar vascular phenotypes, suggesting
that the level of signalling is critical for optimal blood vessel
development. The presence of a misformed vasculature in such
mice suggests that Notch signalling does not function early in
vasculogenesis, but rather regulates subsequent remodelling events
that pattern the vascular network.
The expression of all currently known Notch ligands and
receptors in the developing vasculature has been examined (Villa
et al, 2001). It was found that Notch1, -3 and -4, Delta4, Jagged1
and -2 are all expressed in arteries but not all are expressed by
veins. This pattern of restricted expression to arterial blood vessels
is similar to that of ephrin B2. It was also found that Notch4 and
Delta4 are the only receptor and ligand in the family that are
present in capillaries. These observations implicate the Notch
pathway in the later stages of vascular development, but not the
initial specification of the lineage. There is evidence that the Notch
pathway is involved in responses to vascular injury since Jagged1, -
2 and Notch1, -3 and –4 expression is increased in injured
vascular cells (Lindner et al, 2001). This study also demonstrated
that cell–cell contacts and adhesion plaques are potential targets
of Jagged/Notch signalling because cadherin-mediated intercellular
junctions as well as focal adhesions were modified in cells
transfected with Jagged1. Thus, Jagged regulation of cell–cell
and cell–matrix interactions may contribute to the control of cell
migration in situations of tissue remodelling in vitro. Evidence of
the angiogenic signalling that controls Notch and ligand gene
expression have recently appeared (Liu et al, 2003). Thus, it was
shown that VEGF, but not FGF, induces Notch1 and Delta4
expression in human arterial endothelial cells. Delta4 is of
particular interest to those studying tumour angiogenesis as it is
absent or poorly expressed in adult tissues but shows high
expression in the vasculature of xenografted human tumours and
in endogenous human tumours (Mailhos et al, 2001). Expression
of Delta4 on the tumour vasculature is no doubt a result of it being
one of the recently identified hypoxically induced endothelial
specific genes (Mailhos et al, 2001). This expression pattern
identifies Delta4 (along with magic roundabout, see later) as an
ideal molecule with which to target the tumour vasculature. The
potential of the Notch/Delta system for therapy is as yet largely
unexplored territory.
HEDGEHOG SIGNALLING IN ANGIOGENESIS
Hedgehog proteins have been shown to act as morphogens in
numerous different tissues during embryonic development. They
are 19kDa proteins that interact with heparin on the cell surface
through an N-terminal basic domain and are tethered to the
surface through cholesterol and fatty acyl modification. Hedgehog
signalling is crucial for the formation of limb, lung, gut, hair
follicles and bone. There are three human homologues of the
Drosophila hedgehog gene: sonic hedgehog (Shh), desert hedgehog
(Dhh) and Indian hedgehog (Ihh). Of these, Shh is the most widely
expressed during development and lack of Shh is embryonically
lethal with multiple defects in early to mid-gestation. Ihh is less
widely expressed and mice deficient in Ihh are able to survive until
late gestation but die due to skeletal and gut defects. Dhh-deficient
mice are viable but display peripheral nerve and male fertility
defects.
Signalling by all three Hedgehog proteins occurs through
interaction with the Patched1 receptor, which then activates the
transcription factors Gli1, Gli2 and Gli3. The downstream targets
of the Gli gene products include both patched and Gli themselves,
thus patched and Gli are both components and targets of the Hh
signalling pathway.
Notch Delta Roundabout Ephrin Eph receptor
K
Figure 1 Novel signalling molecules on the endothelial surface involved
in angiogenesis. IgG domain (pentagon), fibronectin-like domain (horizontal
hatched box), EGF-like repeats (diagonal hatched box), cysteine-rich region
(spotted box), DSL domain (circle) and tyrosine kinase domain (K).
Examples known to be present on tumour endothelium are Notch4,
Delta4, magic roundabout, ephrin B2 and EphB3 and -B4.
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angiogenesis. For example, hypervascularisation of the neuroecto-
derm is seen following transgenic overexpression of Shh in the
dorsal neural tube of zebrafish. As with Notch signalling, it appears
that both up- and downregulation of Hh proteins result in vascular
defects. These observations clearly suggest a role for Hh signalling
in angiogenesis but do not actually prove a direct role for the Hh
protein. While Shh has been shown to have an indirect role in
angiogenesis by acting upstream of angiogenic factors (Pola et al,
2001), it has also been shown to be a potent angiogenic agent in
vivo. Thus, when Shh is administered to aged mice it induced new
vessel growth in ischaemic hind limbs. The Shh-induced vessels
showed a characteristically large diameter. Despite this, Shh had
no effect in vitro on endothelial-cell migration or proliferation but
did induce the expression of proangiogenic VEGF and angiopoie-
tins-1 and -2 from interstitial mesenchymal cells. The indirect
nature of hedgehog signalling has been confirmed in zebrafish
(Lawson et al, 2002). Thus, it was shown that zebrafish embryos
lacking Shh activity fail to undergo arterial differentiation, as
defined by the expression of artery-specific markers such as
ephrin-B2a. However, injection of mRNA encoding Shh into the
zebrafish could induce ectopic vascular expression of ephrin-B2a
as did the injection of vegf mRNA (Lawson et al, 2002). The loss of
arterial marker gene expression and ectopic flt4 transcripts in the
dorsal aorta is similar to that of embryos with defective Notch
signalling, suggesting that the vegf and the Notch pathway act in a
common signalling system to induce arterial differentiation. Notch
in the absence of vegf is able to rescue ephrin-B2a expression,
providing evidence for such a common cascade. It seems that Shh
might have a role in the spatial–temporal production of
angiogenic growth factors during embryonic and postnatal
angiogenesis, working upstream of vegf, which in turn operates
upstream of Notch.
SPROUTY AND ANGIOGENESIS
Sprouty (Spry) was first identified in Drosophila as an inhibitor of
fibroblast growth factor (FGF) signalling during tracheal develop-
ment. It is an intracellular protein, localised to the inner leaflet of
the plasma membrane by a cysteine-rich domain. In Drosophila,
Spry is expressed at the tips of growing primary branches of the
tracheal system, in the eye imaginal disc, the embryonic
chordotonal organ precursors and in the midline glia. There are
four isoforms of Spry in mammals, each having a highly conserved
C terminus but variable N terminus. They are all expressed in
restricted patterns in the embryo in early development, showing
dose correlation with sites of FGF signalling suggesting that Spry
proteins may function as negative regulators of FGF signalling
during vertebrate development as well as in Drosophila. In fact, a
decrease in Spry2 expression in the mouse results in increased
lung branching morphogenesis. As with tracheal development, the
process of angiogenesis requires receptor tyrosine kinase signals.
In addition, FGF, VEGF, platelet-derived growth factor, ephrin B
and Tie-2 are all components of both tracheal and blood vessel
development. In view of these many similarities between
Drosophila trachea development and mammalian angiogenesis in
terms of gene function, therefore, it was anticipated that Spry
would also have a role in angiogenesis.
Direct evidence for a role for Spry in angiogenesis comes from a
study in which the mouse Spry4 was overexpressed in the
developing endothelium of a mouse embryo using an adenoviral
vector (Lee et al, 2001). Microangiography was used to examine
the effect of mSpry overexpression in the developing embryo, a
procedure where a phenol red dye was injected into the vitelline
artery of the embryo and the vessels in the embryo were then
visualised by the circulating dye. It was found that embryos
expressing mSpry4 had decreased sprouting of smaller vessels
from the larger ones. By embryo whole mount staining with an
anti-PECAM antibody, it was found that mSpry4 injection resulted
in the development of a primitive vasculature with poor branching
and minimal sprouting of vessels. Furthermore, 24h after
injection, the hearts of the mSpry4 expressing embryos were
beating, but were incompletely developed. When HUVEC in vitro
were transfected with mSpry4 there was a decrease in cell
migration and cell cycle arrest at the G1/S phase with no apoptosis.
The action of Spry4 appears to be via receptor tyrosine kinase
pathways since there was a reduction in both basal and bFGF or
VEGF-induced MAPK phosphorylation in Spry4-expressing cells.
MAPK signalling is involved in the regulation of proliferation,
migration and differentiation during angiogenesis and the inhibi-
tion of tyrosine kinase-stimulated MAP kinase activation probably
accounts for the observed cell cycle arrest. To date it is not known
whether the other sprouty proteins have similar antiangiogenic
properties since the mode of action of sprouty in angiogenesis is
very much in its infancy.
ROUNDABOUTS AND SLITS IN ANGIOGENESIS
Roundabouts and slits comprise a family of signalling molecules
thought to be restricted to cells of neuronal lineage. Roundabout
was so named because of the neuronal phenotype arising from its
deletion in Drosophila. The slits and roundabouts are involved in
axon guidance where the three known human slits and two
roundabout receptors mediate a repulsive signal. The recent
identification of magic roundabout (ROBO4), a novel roundabout
receptor restricted to endothelial cells was unexpected (Humi-
niecki and Bicknell, 2000). In situ analysis has shown magic
roundabout to be absent from adult tissues, but strongly expressed
on the vasculature of tumours including those of the brain, bladder
and colon metastasised to the liver (Huminiecki et al, 2002). These
observations identify magic roundabout as a promising therapeu-
tic target.
CONCLUSIONS
It is arguably true to say that few researchers in the field of
angiogenesis expected the growth of new blood vessels to be a
simple event, nevertheless the molecular complexity of the process
and the number of pathways involved has been a surprise. A
significant outcome of this complexity has been the pleasing
number of potential new targets available for therapeutic
intervention. Studies of antiangiogenesis and vascular targeting
are clearly at an exciting stage.
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